Limits...
CD24 expression as a marker for predicting clinical outcome in human gliomas.

Deng J, Gao G, Wang L, Wang T, Yu J, Zhao Z - J. Biomed. Biotechnol. (2012)

Bottom Line: However, the correlation of its expression with clinicopathological parameters of gliomas and its prognostic significance in this tumor remain largely unknown.As per the results, CD24 was overexpressed in gliomas.Its expression levels in glioma tissues with higher grade (P < 0.001) and lower KPS (P < 0.001) were significantly higher than those with lower grade and higher KPS, respectively.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurosurgery, Institute for Functional Neurosurgery PLA, TangDu Hospital, Fourth Military Medical University, Baqiao District, Xi'an, China.

ABSTRACT
CD24 is overexpressed in glioma cells in vitro and in vivo. However, the correlation of its expression with clinicopathological parameters of gliomas and its prognostic significance in this tumor remain largely unknown. To address this problem, 151 glioma specimens and 10 nonneoplastic brain tissues were collected. Quantitative real-time PCR, immunochemistry assay, and Western blot analysis were carried out to investigate the expression of CD24. As per the results, CD24 was overexpressed in gliomas. Its expression levels in glioma tissues with higher grade (P < 0.001) and lower KPS (P < 0.001) were significantly higher than those with lower grade and higher KPS, respectively. Cox multifactor analysis showed that CD24 (P = 0.02) was an independent prognosis factor for human glioma. Our data provides convincing evidence for the first time that the overexpression of CD24 at gene and protein levels is correlated with advanced clinicopathological parameters and poor prognosis in patients with glioma.

Show MeSH

Related in: MedlinePlus

Immunohistochemical staining of CD24 protein in tumor cells of high-grade glioma (a) and nonneoplastic brain (b) tissues (original magnification ×400). Staining for this antigen is described in Section 2. Positive staining of CD24 is seen in the cytoplasm and membrane of tumor cells in gliomas, whereas the nonneoplastic brain tissues showed no expression of CD24.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3303885&req=5

fig1: Immunohistochemical staining of CD24 protein in tumor cells of high-grade glioma (a) and nonneoplastic brain (b) tissues (original magnification ×400). Staining for this antigen is described in Section 2. Positive staining of CD24 is seen in the cytoplasm and membrane of tumor cells in gliomas, whereas the nonneoplastic brain tissues showed no expression of CD24.

Mentions: CD24 expression was studied in a total of 151 glioma specimens of which 68 were low grade glioma (grade I and II) and 83 were high grade (grade III and IV). About 10 specimens taken from nonneoplastic brain tissues served as control group. Based on the immunohistochemistry analysis, CD24 was expressed in the cytoplasm and membrane of tumor cells in gliomas (Figure 1(a)), whereas the nonneoplastic brain tissues showed no expression of CD24 (Figure 1(b)). Among the glioma specimens, 110 (72.8%) glioma specimens were positively stained, and 41 (27.2%) glioma specimens were negatively stained. We also found a significant difference of CD24 expression between glioma and nonneoplastic brain tissues (P < 0.001).


CD24 expression as a marker for predicting clinical outcome in human gliomas.

Deng J, Gao G, Wang L, Wang T, Yu J, Zhao Z - J. Biomed. Biotechnol. (2012)

Immunohistochemical staining of CD24 protein in tumor cells of high-grade glioma (a) and nonneoplastic brain (b) tissues (original magnification ×400). Staining for this antigen is described in Section 2. Positive staining of CD24 is seen in the cytoplasm and membrane of tumor cells in gliomas, whereas the nonneoplastic brain tissues showed no expression of CD24.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3303885&req=5

fig1: Immunohistochemical staining of CD24 protein in tumor cells of high-grade glioma (a) and nonneoplastic brain (b) tissues (original magnification ×400). Staining for this antigen is described in Section 2. Positive staining of CD24 is seen in the cytoplasm and membrane of tumor cells in gliomas, whereas the nonneoplastic brain tissues showed no expression of CD24.
Mentions: CD24 expression was studied in a total of 151 glioma specimens of which 68 were low grade glioma (grade I and II) and 83 were high grade (grade III and IV). About 10 specimens taken from nonneoplastic brain tissues served as control group. Based on the immunohistochemistry analysis, CD24 was expressed in the cytoplasm and membrane of tumor cells in gliomas (Figure 1(a)), whereas the nonneoplastic brain tissues showed no expression of CD24 (Figure 1(b)). Among the glioma specimens, 110 (72.8%) glioma specimens were positively stained, and 41 (27.2%) glioma specimens were negatively stained. We also found a significant difference of CD24 expression between glioma and nonneoplastic brain tissues (P < 0.001).

Bottom Line: However, the correlation of its expression with clinicopathological parameters of gliomas and its prognostic significance in this tumor remain largely unknown.As per the results, CD24 was overexpressed in gliomas.Its expression levels in glioma tissues with higher grade (P < 0.001) and lower KPS (P < 0.001) were significantly higher than those with lower grade and higher KPS, respectively.

View Article: PubMed Central - PubMed

Affiliation: Department of Neurosurgery, Institute for Functional Neurosurgery PLA, TangDu Hospital, Fourth Military Medical University, Baqiao District, Xi'an, China.

ABSTRACT
CD24 is overexpressed in glioma cells in vitro and in vivo. However, the correlation of its expression with clinicopathological parameters of gliomas and its prognostic significance in this tumor remain largely unknown. To address this problem, 151 glioma specimens and 10 nonneoplastic brain tissues were collected. Quantitative real-time PCR, immunochemistry assay, and Western blot analysis were carried out to investigate the expression of CD24. As per the results, CD24 was overexpressed in gliomas. Its expression levels in glioma tissues with higher grade (P < 0.001) and lower KPS (P < 0.001) were significantly higher than those with lower grade and higher KPS, respectively. Cox multifactor analysis showed that CD24 (P = 0.02) was an independent prognosis factor for human glioma. Our data provides convincing evidence for the first time that the overexpression of CD24 at gene and protein levels is correlated with advanced clinicopathological parameters and poor prognosis in patients with glioma.

Show MeSH
Related in: MedlinePlus